



MEDIA RELEASE

8 February 2023

Oncology One Appoints New Non-Executive Director, Dr Ton Bunt

Australian biotechnology company, Oncology One, has today announced the appointment of a new Non-Executive Director, Dr Ton Bunt, a highly accomplished biotechnology executive and medically trained physician.

8 February 2022, Melbourne, Australia: Australian biotech company, Oncology One Pty Ltd (the Company), today announced it has appointed Dr Ton Bunt as a Non-Executive Director, who brings vital expertise to the Board in the areas of product development and commercialisation.

Dr Bunt is a medically trained physician, with a PhD in gastric surgery from the Leiden University in The Netherlands, and an MBA from The Wharton School of the University of Pennsylvania.

Oncology One Chair, Mary Harney, said: *"The Oncology One Board enthusiastically welcomes Dr Bunt. He has enviable credentials in the biotechnology and pharmaceutical sectors, with targeted experience in transactions and commercialisation of research and development (R&D) - all highly important areas for our Company, as we translate early-stage research into therapies that transform outcomes for people with cancer."*

Dr Bunt is Co-Founder, CEO and Director of Izumi Biosciences Inc., a specialist biotech company based in Boston US, developing better drugs for serious diseases of the nervous system. As a private consultant, he has also acted as a transaction adviser with a deal track record of six licensing and M&A transactions with more than \$1B in cumulative value.

Dr Bunt co-led pharmaceutical company (ALBO) in strategic partnering, reverse IPO and \$30mm follow-on financing. As CMO and head of R&D at specialty pharmaceutical company Oscient Pharmaceuticals Corporation (OSCI), Dr Bunt achieved key clinical and regulatory milestones, including negotiating a Special Protocol Assessment with US-FDA, completing multiple pivotal studies and securing NDA approvals.

Dr Bunt said joining the Oncology One Board is an opportunity to make a meaningful contribution to the sector, early in the life cycle of vital new therapeutics.

"I am proud to join such a respected group of industry leaders on the Oncology One Board, who share a deep motivation to support translational research by partnering strategically to identify, acquire, develop and commercialise emerging small molecule oncology treatments. The Company's work in the area of small molecule cancer drugs is cutting edge in exploring highly novel and emerging therapeutic targets, and I look forward to contributing to this exciting work."

To learn more about investment or partnership opportunities with Oncology One, visit oncologyone.com.au.

-ENDS-

Media Contact



To arrange an interview with Oncology One CEO, Dr Joanne Boag, please contact:

HACK Director, Haley Chartres
m. 0423 139 163
e. haley@hck.digital



About Oncology One

Oncology One Pty Ltd is a small molecule oncology drug development company. Our strategy centres on building a diversified portfolio of small molecule candidates that are highly differentiated and address unmet clinical needs. We work with partners to identify suitable programs and build value in high potential drug discovery projects. Oncology One has one out-licensed program and several early-stage projects in partnership with Australian research institutions. Oncology One is a private company headquartered in Melbourne, Australia. For more information visit oncologyone.com.au.